Results 71 to 80 of about 424,058 (165)

HIV‐1 viral load and reservoir size remain stable following SARS‐CoV‐2 mRNA vaccination in people with HIV

HIV Medicine, EarlyView.
Abstract Background The potent immunogenicity of mRNA vaccination raised concerns about its impact on HIV‐1 viral load (VL) and reservoir size in people with HIV, which could drive vaccine hesitancy. As part of a prospective clinical trial, we investigated whether SARS‐CoV‐2 mRNA vaccination induced changes in VL and reservoir size after a 1‐year three‐
Oscar Kieri, Bianca B Jütte, Jan Vesterbacka, Soo Aleman, Hans‐Gustaf Ljunggren, Marcus Buggert, J Peter Svensson, Anders Sönnerborg, Piotr Nowak   +8 more
wiley   +1 more source

DataSheet_1_Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection.docx

, 2022
Three COVID-19 vaccines have received FDA-authorization and are in use in the United States, but there is limited head-to-head data on the durability of the immune response elicited by these vaccines.
Jeffrey M. Wilson (3036432), Will H. Eschenbacher (12267677), Barbara J. Mann (270746), Michael R. Nelson (12267683), Thomas A.E. Platts-Mills (5425607), Nathan E. Richards (12267668), Emily C. McGowan (12267680), Lyndsey M. Muehling (12267671), Jaimin Patel (3257574), Behnam Keshavarz (12267665), Savannah G. Brovero (10702084), Deborah D. Murphy (4050487), Judith A. Woodfolk (4050496), Alexandra Kadl (12267686), Lisa J. Workman (11939969), Glenda Canderan (244202), Samuel M. Ailsworth (12267674)   +16 more
core   +1 more source

Kidney Transplant Recipients Develop Nasal Mucosal Antibodies to SARS‐CoV‐2 With ACE2‐Inhibiting Activity Following mRNA Vaccination

Transplant Infectious Disease, EarlyView.
Kidney transplant recipients develop nasal mucosal antibodies after systemic COVID‐19 vaccination, which are able to inhibit binding of SARS‐CoV‐2 to the ACE2 receptor, but at a lower concentration than the general population. ABSTRACT Background Less than 60% of kidney transplant recipients (KTRs) become IgG seropositive for the viral spike (S ...
Vera J. C. H. Koomen, Christa E. van der Gaast‐deJongh, Fred van Opzeeland, Ria Philipsen, Marije C. Baas, A. Lianne Messchendorp, Frederike J. Bemelman, Marcia M. L. Kho, Carla C. Baan, Debbie van Baarle, Jan‐Stephan F. Sanders, Rob van Binnendijk, Gerco den Hartog, Ron T. Gansevoort, Renate G. van der Molen, Luuk B. Hilbrands, Dimitri A. Diavatopoulos   +16 more
wiley   +1 more source

Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison

, 2021
Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a ...
Dorothy Leidner (13067292), David M Studdert (15655535), Yifan Zhang (119570), Jason R Andrews (14320521), Ying Li (38224), Lea Prince (178357), Elizabeth T Chin (15655532), Jeremy D Goldhaber-Fiebert (15655538), Joshua A Salomon (8674386), Elizabeth Long (3342410)   +9 more
core   +1 more source

A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children

Expert Review of Vaccines
Introduction Vaccination against SARS-CoV-2 is an integral pillar of the public health approach to COVID-19. With the emergence of variants of concern that increase transmissibility and escape from vaccine- or infection-induced protection, vaccines have ...
Frances Priddy, Spyros Chalkias, Brandon Essink, Jordan Whatley, Adam Brosz, Ivan T. Lee, Jing Feng, LaRee Tracy, Weiping Deng, Wen Zhou, Honghong Zhou, Avika Dixit, Sabine Schnyder Ghamloush, Bethany Girard, Elizabeth de Windt, Anne Yeakey, Jacqueline Miller, Rituparna Das, Barbara J. Kuter   +18 more
doaj   +1 more source

Efficacy and Safety of Messenger RNA Vaccines

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims The rapid development of mRNA vaccines has revolutionized infectious disease prevention and cancer immunotherapy. While their efficacy is well established, concerns about safety and immunopathological risks persist. This study aims to evaluate the immunogenicity, safety profiles, and design considerations of mRNA vaccines ...
Kesaobaka Batisani, David Chisompola
wiley   +1 more source

Adverse events reported after administration of BNT162b2 and mRNA-1273 COVID-19 vaccines among hospital workers: a cross-sectional survey-based study in a Spanish hospital

, 2022
The World Health Organization declared COVID-19 a pandemic in March 2020. The first vaccine became available in December, with practically no post-marketing data. An analytical cross-sectional survey-based study was conducted in a third-level hospital in
Miguel Ángel (MA) Calleja-Hernández (11910136), Marta (M) Valera-Rubio (11910118), María Isabel (MI) Sierra-Torres (11910121), Jaime (J) Cordero-Ramos (11910127), María Reyes (MR) López-Márquez (11910130), Óscar (O) Cruz-Salgado (11910133), Raquel (R) Castillejo García (11910124)   +6 more
core   +2 more sources

Time and cost of administering COVID-19 mRNA vaccines in the United States

Human Vaccines & Immunotherapeutics, 2021
In early 2020, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) outbreak a global pandemic. In response, two novel messenger RNA (mRNA)-based vaccines: mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) were rapidly ...
Benjamin Yarnoff, Steven Bodhaine, Ed Cohen, Philip O. Buck   +3 more
doaj   +1 more source

The Association Between MOG‐IgG Positivity and mRNA SARS‐CoV‐2 Vaccination in Denmark: A Self‐Controlled Case Series Study

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Purpose Spontaneous reporting of a possible link between myelin oligodendrocyte glycoprotein (MOG) antibody‐associated disease (MOGAD) and mRNA SARS‐CoV‐2 vaccination warrants further examination. Hence, the objective of this study was to investigate the association between MOG‐IgG positivity as a proxy for MOGAD and mRNA SARS‐CoV‐2 ...
Tine Iskov Kopp, Anne Katrine Andreasen, Viktoria Papp, Mette Hjorslev Knudgaard, Heidi Jeannet Graff, Michelle S. Clement, Nicklas Hasselblad Lundstrøm, Stine Ulsø, Mona El‐Sayed Hervig, Charlotte Wessel Skovlund   +9 more
wiley   +1 more source

Comparative mRNA booster effectiveness against death or hospitalization with COVID-19 pneumonia across at-risk US Veteran populations

Nature Communications, 2023
Studies of comparative mRNA booster effectiveness among high-risk populations can inform mRNA booster-specific guidelines. The study emulated a target trial of COVID-19 vaccinated U.S.
J. Daniel Kelly, Samuel Leonard, W. John Boscardin, Katherine J. Hoggatt, Emily N. Lum, Charles C. Austin, Amy Byers, Phyllis C. Tien, Peter C. Austin, Dawn M. Bravata, Salomeh Keyhani   +10 more
doaj   +1 more source